Global Custom Market Research Reports Provider Company

phone

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018

  • Published Date: 27 Feb 2018
  • Number of Pages: 128
  • Category: Pharmaceuticals
  • Country: Global

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 3, 1, 23, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Publisher Name : Global Markets Direct


Introduction 4
Chemotherapy Induced Peripheral Neuropathy - Overview 5
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development 6
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment 14
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development 24
Chemotherapy Induced Peripheral Neuropathy - Drug Profiles 33
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects 110
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products 112
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones 113
Appendix 123



List Of Tables

List of Tables
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Corp, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Insys Therapeutics Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2018
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2018 (Contd..1), H1 2018
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2018



List Of Figures

List of Figures
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018



Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018 According to the recently published report Transmembrane Prolyl 4 Hydroxylase -

View Report

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018 CD40 Ligand (T

View Report

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2018 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports